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Assessment of the Mutagenicity
of Phthalate Esters
by Walter J. Kozumbo,* Rosanna Kroll* and
Robert J. Rubin*
The Ames assay was used to investigate the mutagenicity of several phthalate esters as an
approximation oftheircarcinogenic potential. Theorthodiesters, dimethyl phthalate (DMP) and
diethyl phthalate (DEP) produced a positive dose-related mutagenic response with Salmonella
TA100, but only in the absence of S-9 liver enzymes. Dibutyl, di(2-ethylhexyl), mono(2-
ethylhexyl), and butyl benzyl phthalate as well as the dimethyl isophthalate and terephthalates
and the trimethyl ester, trimellitate, were not mutagenic with TA100 or TA98 in the presence or
absence ofS-9. In a host-mediated assay, extracts of24-hr urines ofrats injected IP with DMP (2
g/kg) were not mutagenic to TA100 at levels up to 8 equivalent-ml of urine/plate (representing
30% of their daily urinary output). In vitro studies revealed that S-9 associated esterase
hydrolyzed DMP to the monoester and methanol and eliminated its mutagenicity. Whole rat
skin was shown to have about 1.5% ofthe DMP-esterase activity ofliver, whencompared on awet
weight basis. An in vitrobinding study indicated that epidermal macromolecules bound DMP at a
severalfold greater rate than hepatic macromolecules. Thus, both the mutagenicity and binding
ofDMP are inversely related tothe metabolism ofthis compound. These results suggest that skin
could be at high risk for a mutagenic/carcinogenic insult.
Introduction
Since there are scant data on the mutagenic and
carcinogenic potential of a variety of phthalate
esters, the Ames assay was used to investigate the
mutagenicity of some of these compounds as an
approximation of their carcinogenic potential. This
paper presents evidence for the mutagenesis of
dimethyl phthalate (DMP) and diethyl phthalate
(DEP), alongwith additional studies onthemetabo-
lism of DMP and its binding to macromolecules.
DMP is a widely used insect repellent which is
availabletothegeneralpublic as anactiveingredient
in commercial products. In its pure form it is used
by agricultural workers in doses up to 100 mg/kg
applied directly to the skin (1) and by the U.S.
military in tropical regions of the world. Consider-
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ingthe many people exposed to DMP as well as the
potentially large doses to which they may be
exposed, further research on the mutagenic effects
of this chemical is well justified.
A literature search in the area ofmutagenicity of
DMP revealed relatively few studies. One study by
Pilinskaya et. al. (2) reported no increase in chro-
mosomal aberrations in bone marrow cells ofwhite
mice administered DMP intraperitoneally (dose not
cited). Another study by Tsuchiya and Hattori (3)
also reported no increase in chromosomal damage
in human leukocytes treated in culture with 20
,ug/ml of DMP. On the other hand, Yurchenko (4)
did report a significant increase in chromosomal
aberrations in hepatocytes from rats treated topi-
cally with 1250 mg/kg DMP five times per week for
one month. Rats administered only a single topical
dose displayed no significant increase in chromo-
somal aberrations. Thus, DMP's topical use as an
insect repellent and the observation of hepatic
chromosomal damage would suggest skin and liver,
respectively, as potential sites for mutagenic/car-
cinogenic effects.104
Methods
Mutagenesis
The standard Ames bacterial mutagenicity assay
(5) was used with severalmodifications as described
by Batzinger et al. (6). The major modifications
included shifting the histidine and biotin (at concen-
trations of50 and 15 g/plate, respectively) from the
top to the bottom agar, and reducing the glucose to
67.5 mg/plate in the bottom agar. Each phthalate
ester was tested with Salmonella typhimurium
strainsTA98andTA100inthepresence and absence
of S-9 liver microsomal fraction from male Sprague-
Dawley rats induced with Aroclor 1254.
Host-Mediated Assay
Male Sprague-Dawley rats (approximately 350 g)
were injected IP with 2 g/kg of DMP and 24-hr
urine was collected. The urine from 12 animals was
pooled. Five such pools were collected. The urine
(not further acidified) was extracted once with
n-butanol which was then evaporated. The residue
was dissolved in DMSO and tested in the Ames
assay. Aliquots representing various equivalent vol-
umes of urine from each pool were tested.
Chemical Analysis of Urine
The 24-hr pooled urine from a group of 12 rats
(approximately 350 g) was acidified to pH 1-2 with
HClandthenexhaustivelyextractedwithn-butanol
until no UV-absorbing phthalate moieties could be
detected in the urine by direct thin-layer chroma-
tographic (TLC) analysis. Thebutanolextractswere
combined and examined by TLC. The UV absor-
bant spots corresponding to the Rfvalues ofmono-
methyl phthalate (MMP) and DMP standards were
scraped from the plates and extracted with metha-
nol. The spectrophotometric absorbance ofthe meth-
anol extracts at 275 nm was used to determine the
amount ofphthalatepresent. NootherUV-absorbing
spots were seen on the TLC plates.
Preparation, Incubation and
Treatment of Skin Slices
The backs ofmale Sprague-Dawley rats between
300 and 400 gwere shaved 24 hrpriorto sacrifice by
cervical dislocation. Dorsal skin was removed imme-
diately after sacrifice and the fat and loose connec-
tive tissue adhering to the hypodermis was scraped
away with a scalpel. The skin, now consisting of
dermis and epidermis, was sliced, weighed and
placed into phosphate buffered saline (PBS), pH
7.4, at a ratio of 1 to 5 (w/v). DMP was added to a
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final concentration of 1.5 mg/ml. The incubation
mixture was shaken at 37°C for various time peri-
ods up to 2 hr before the reaction was terminated
with the addition of sufficient l.ON HCI to reduce
the pH to approximately 1.5. The acidified medium
was decanted and the skin slices were washed
several times with PBS while maintaining the pH
at 1-2. The washes were pooled with the original
medium and the total volume was extracted with
chloroform until no phthalate moieties could be
detected by direct TLC analysis of the aqueous
pooled fraction. In addition, the skin slices were
alsorinsed severaltimes with chloroform. The chlo-
roform extracts ofboth the skin slices and aqueous
medium were pooled and centrifuged at lOOOg for
10 min. The supernatant was then fractionated by
TLC and the content ofMMP and DMP determined
as above.
Preparation, Incubation and Treatment
of Liver S-9
A 0.15 ml aliquot ofDMP (4000 ,ug/ml water) was
added to 2 ml of E medium plus 0.5 ml of S-9 mix
(5). The mixture was shaken at 37°C for various
time periods up to 1 hr. The reaction was termi-
nated by the addition of0.4 ml of 1.0 N HCI. After
centrifugation at 1000 g for 10 min, 2 ml of the
acidified supernatant (pH 1.5) was extracted twice
with chloroform.
Chemical Analysis of In Vitro Skin and
Liver Extracts
The rate ofin vitro metabolism of DMP to MMP
and methanol was measured by the formation of
MMP. The chloroform extracts from the liver S-9
and the skin incubations were analyzed for MMP by
the TLC-spectrophotometric method described in
the above section on chemical analysis ofurine. The
rate ofmetabolism was determined over the linear
range of metabolism for each tissue.
In addition, the in vitro metabolism of DMP to
methanol by skin slices was investigated using the
basic method of Wood and Siddiqui (7). A slight
modificationofthe method allowed forsimultaneous
determination offormaldehyde formation. This was
accomplished by measuring the amount of formal-
dehyde formed in the presence and absence of
KMnO4, which is used to convert methanol to form-
aldehyde. In the presence of KMnO4, the total of
methanol plus formaldehyde is measured. In the
absence of KMnO4, only the presence of formalde-
hyde is detected. The difference between the two
procedures yields the amount of methanol formed.MUTAGENICITY ASSESSMENT OF PHTHALATE ESTERS
Preparation of Epidermal and Hepatic
Homogenates
The homogenized epidermis was prepared by
modifications of previously described techniques
(8). After the removal of the entire dorsal skin as
described above, it was immersed in distilled water
at 50°C for30 sec and thenimmediately transferred
to iced water for another half minute. The epider-
mal layer was then scraped off with a scalpel,
suspended in 2-3 ml of ice cold PBS (pH 7.4) and
homogenized. The homogenate was then strained
through a fine nylon mesh.
A rat was decapitated and following exsanguina-
tion the in situ liver was perfused with 30-40 ml of
PBS (pH 7.4) via the hepatoportal vein. The liver
was then removed and homogenized in PBS at a
ratio of 1 to 3 (w/v). The homogenate was strained
through fine nylon mesh.
A 1-ml aliquot of each of epidermal and liver
homogenates was mixed with 1 ml of14C-carbonyl-
labeled DMP solution (3.0 mg/ml of DMP in PBS),
representing from 1.4 x 105 to 2.0 x 106 dpm per
vial. The incubation mixtures were shaken at 37°C
for 2 hr and the reaction terminated and the mac-
romolecules precipitated with the addition of4.0 ml
of 0.9M trichloroacetic acid (TCA).
Determination of
Macromolecular Binding
Todeterminemacromolecularbinding, themethod
ofJollow et al. (9) was employed. Successive wash-
ings with TCA, 80% ethanol and acetone were
continued until the 1 ml aliquots of the wash solu-
tion (dissolved in ACS Aquasol scintillation fluid)
produced counts equivalent to background on a
Packard Tricarb liquid scintillation spectrometer.
The final acetone washed TCA precipitate was
taken to dryness and weighed to determine the mg
ofdry weight. Finally, the macromolecular residue
was solubilized inNCStissue solubilizer(Amersham)
for counting.
Results
The results from the modified Ames mutagenic
assay of phthalic acid (PA), DMP and DEP in
TA100 in the absence of S-9 are shown in Table 1.
Hyeanthone was used as the positive control; it
consistently produced a response of greater than
600 netrevertants at aconcentration of30 ,ug/plate.
PA, the de-esterified product of phthalate esters,
proved negative in this assay. However, both DMP
and DEP registered a positive and dose-related
response. At 1000 ,ug the mutagenic response rep-
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Table 1. Mutagenesis assay of PA, DMP and
DEP in Salmonella typhimurium TA100.
Revertants pertreatedplate SEMa
Test compound 1±g/plate Revertants per control plate
Hyeanthone 30 3.49 ± 0.14
PA 100 1.11 ± 0.07
300 0.95 ± 0.02
1000 0.90 ± 0.07
DMP 100 0.82 ± 0.03
500 1.45 ± 0.job
1000 1.84 ± 0.12b
DEP 100 1.06 ± 0.05
500 1.26 ± 0.09b
1000 1.90 ± o.ob
aThe control orbackground reversion frequency was 291 ± 20
(n = 14). Each value represents the mean from 3-5 replicate
experiments. In each experiment duplicate plates were run for
each condition.
bp < 0.05 by Student's t-test when tested for difference from
1.00.
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FIGURE 1. Mutagenic doseresponse for DMP. Eachmutagenic
value represents a mean from two or more replicate experi-
ments in which duplicate plates (histidine-deficient) were
used at each concentration. Percent survivalwas determined
in the following way: known dilutions ofTA100 were plated
onthenutrientagar (histidine-containing) eitherinthe absence
of DMP (control) or in the presence of known amounts of
DMP (treated). After48 hr ofincubation, numbers ofsurviv-
ing mutant colonies on the treated plates were compared to
control. The asterisk denotes p < 0.025 by Student's t-test
when tested for differences from 1.0.Table 2. Effect of S-9 supplementation on the Ames assay of DMP and DEP in TA100.
Revertants per treated plate ± SEMa
Revertant per control plate
With S9
Test compound ,g/plate No S-9 +NADP +NAD No cofactors
Lucanthone 30 1.04 ± 0.04 2.34 ± 0.13 - -
DMP 1000 1.72 ± 0.14b 1.00 ± 0.04 1.03 ± 0.04 1.11 ± 0.04
DEP 1000 1.58 ± 0.21b 0.76 ± 0.07 0.69 ± 0.08 0.77 ± 0.08
aThe control or background reversion frequency was 253 + 16 (N = 11) in the absence of S-9 and 209 ± 10 in the presence of S-9.
bp 0.05 by Student's t-test when tested for difference from 1.00.
resented essentially a doubling ofthe basal level of
reversion. These three compounds were not muta-
genic when tested with the TA98 strain of Salmo-
nella (data not shown).
The effect ofS-9 liver extract on DMP- and DEP-
inducedmutationsispresentedinTable2. Lucanthone
(Luc) wasused asthepositive controltodemonstrate
the effectiveness ofthe S-9 fraction in activating a
nondirect-acting mutagen. In the absence of S-9,
DMP and DEP produced a positive mutagenic
response, confirming the data presented in Table 1.
With S-9 and NAD or NADP added to the system,
the positive response was reversed. It is important
to note that S-9 alone (without the cofactors) also
eliminated the mutagenic resDonse.
A number of other phthalate esters were tested
in our modified Ames assay. Each phthalate was
assayed with bacterial strains TA100 and TA98,
bothinthepresence and absenceofS-9liverextract.
All of these phthalate esters failed to produce a
positive response at concentrations up to 1000
,ug/plate. The compounds tested were: di-n-butyl
phthalate, di(2-ethylhexyl) phthalate, mono(2-ethyl-
hexyl) phthalate and butyl benzyl phthalate (data
not shown).
Figure 1 shows the mutagenic dose response for
DMP extended over a broader range of concentra-
tions, i.e., from 1 to 4 mg/plate. A positive dose-
related mutagenic response was associated with a
dose-related decrease in survival ofthe cells ofthe
TA100 tester strain. If the absolute number of
revertants per plate were corrected for percent
survival, anevengreatermutagenicresponsewould
have been seen than the 3- to 3.5-fold response at 4
mg/plate.
Thestructure-activityrelationship (SAR)ofDMP
was investigated by testing three other methyl
phthalatesintheAmesassaywithTA100andTA98,
either in the absence or presence of S-9 activation.
Dimethyl terephthalate (I), dimethyl isophthalate
(II) and trimethyl trimellitate (III) were all nega-
tive in the mutagenesis assay.
The results of a host-mediated mutagenic assay
of DMP in rats are presented in Figure 2. There
were no statistically significant differences in the
numberofrevertantsperplateforcontrolortreated
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urines (over a range of 1 to 8 ml urine) when
compared to blank plates. A volume of8 ml ofurine
represents approximately 50% of the daily output
ofcontrol rats and about 30% ofthe daily output of
treated rats. This difference in the fraction of the
total daily urinary output represented by a given
volume of the two urines was due to a marked
diuresis in the DMP-treated rats.
The lack of a mutagenic response to extracts
equivalent to up to 8 ml of treated urine (approxi-
mately 30% the daily output) led us to assay the
extractsforDMPand otherphthalic acid-containing
metabolites. These extracts were found to have
0.06 mg/ml ofDMP and 1.90 mg/ml ofthe mono-de-
esterified product, monomethyl phthalate (MMP).
No other phthalic acid-containing derivatives were
found. Thus the mutagenesis plates containing the
equivalent of 8 ml of treated urine would have
contained 480 ,ug of DMP and 15.2 mg of MMP.
Previous experiments (data not shown) had shown
that MMP was not mutagenic in TA100 at levels up
to 24 mg per plate.
Since the urinary extracts used in the host-
mediated assay were obtained by a single n-butanol
extraction of urine that was not further acidified
beyond its native pH (see methods), further exper-
iments were conducted to determine the phthalic
acid-containing components in urine oftreated rats
using more exhaustive extractions from samples
that were acidified to pH 1-2 with HCl. The data
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are shown in Table 3. DMP and MMP were found at
levels of0.14 and 15.70mg/ml, representing0.6 and
67.0%oftheinjecteddose, respectively. Onceagain,
no other phthalic acid-containing derivatives were
detected. Thus, DMP represented less than 1% of
all phthalic acid-containing molecules excreted in24
hr.
Although these results suggest systemic inacti-
vation of the mutagenic activity of DMP, it should
be recalled that the major route ofhuman exposure
is topical. Therefore, the ability of rat skin to
metabolize DMP to MMP and thus inactivate the
diester was investigated. The results from three
separate experiments performed to study the in
vitro metabolism ofDMP by rat skin are presented
in Table 4. In the first experiment, only MMP
formation was assayed; it was found to be 3.47
nmole/hr/mg tissue. Since the de-esterification of
DMP should also result in the formation of metha-
nol, the rate for this product was measured in a
second experiment. It was found to be 2.58 nmole/
hr/mg tissue. In a third experiment the stoichio-
Table 3. DMP and MMP in the 24-hr urine ofrats injected IP
with DMP at a dose of 2 g/kg.
Compound Ester in urine, mg/ml % of injected dose
MMP 15.70 67.0
DMP 0.14 0.6
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FIGURE 2. Host-mediated mutagenic assay of DMP in rats. Blank plates contained no urine and the data for these are shown on the
y-axis. No toxicity (as measured by percent survival on nutrient agar) was seen in TA100 with extracts ofeither control or treated
urine at levels up to 8.0 ml. Data points without standard error bars are the means ofvalues from two independent experiments.
Those with standard error bars represent an n of 3 or more. Student's t-test for these values showed no statistical significance
when compared to the data from the blank plates.
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Table 4. In vitro metabolism of DMP by whole slices of rat
skin.a
Dimethyl Phthalate -* Monomethyl Phthalate + Methanol
(DMP) (MMP)
MMP formed, MeOH formed, HCHO formed,
Exp. nmole/hr/mg nmole/hr/mg nmole/hr/mg
no. tissue (wet) tissue (wet) tissue (wet)
1 3.47
2 2.58
3 2.16 2.18 0
aIn vitro rate of metabolism of DMP by rat liver S-9: 165
nmole MMP formed/hr/mg liver (wet).
Table 5. In vitro binding of DMP.'
Liver
Epidermis
DMP bound, nmole/mg tissue
(TCAprecipitable dryweight)X ± SEM
0.17 ± 0.01
0.98 ± 0.l9b
aEach value represents the mean of four separate assays.
bp 0.025 by Student t-test when tested for difference from
0.17 (mean binding value of CMP for liver homogenate).
metric relationship between MMP and methanol
was examined and found to be 1:1. The rate of
formaldehyde formation was also investigated in
this latter experiment, but none of this product
could be detected. It should be noted that the rate
ofde-esterification ofDMP by whole skin is approx-
imately 1.5% of the rate seen in the liver, when
compared on a mg wet weight basis.
Given the markedly lower rate of metabolism of
DMP to a nonmutagenic metabolite in skin relative
to liver, the in vitro binding of DMP to tissue
macromolecules in these two tissues was investi-
gated. The results are shown in Table 5. 14C-Carbo
nyl-labeled DMP was found to bind to hepatic and
epidermal macromolecules at levels of0.17 and 0.98
nmole/mg tissue (dry weight-TCA precipitable),
respectively.
Discussion and Conclusion
The positive dose-related mutagenic response of
TA100 to DMP and DEP (Table 1) in the Ames
assay was shown to be affected or modified by two
factors. One of these is the molecular structure of
DMP, as revealedbythe SAR study on the effect of
position and number ofmethyl estermoieties on the
benzene ring. The failure of the meta and para
dimethyl esters to elicit a positive response in the
Ames assay emphasizes the importance ofthe ortho
configuration. The addition of a third methyl ester
to the 4-position of DMP and resultant elimination
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of the mutagenic response indicates the necessity
for the ortho diester arrangement. However, test-
ing of the 1,2,3-trimethyl phthalate is necessary
before any conclusive statements can be made in
reference to the mutagenic potential of trimethyl
esters. Another SAR-related effect is important to
note. From the series of phthalate esters tested
only the shorter chained and more hydrophilic of
the aliphatic phthalate diesters, DMP and DEP,
are mutagenic in the bacterial assay.
Theeliminationofthepositivemutagenicresponse
by S-9 livermicrosomes(Table2)implicates metabo-
lism as a second important modifying factor. Lack
of involvement of the cofactors NAD and NADP
indicates that the classical mixed-function oxidase
(MFO) system is not involved in the apparent met-
abolic elimination ofthe mutagenic response. Liver
S-9 (Table 4) readily metabolizes DMP to MMP,
which has been shown to be a nonmutagenic com-
pound in the Ames assay. These results suggest
thata S-9 associated esterase activityis responsible
for the elimination ofthe mutagenic effect. Results
from the host-mediated mutagenic assay (Fig. 2)
support this idea. In this assay approximately 97%
ofthe phthalate estercontent ofthe urine extract is
MMP. Thus, thelackofapositivemutagenicresponse
alongwiththe preponderance ofmonoesterindicate
the importance of DMP-monoesterase activity in
eliminating the mutagenic effect and possibly in
affording protection to tissue exposed to DMP.
It should be noted that 8 equivalent ml oftreated
urine are negative inthe mutagenic assayin spite of
containingapproximately480jigofDMP, anamount
which results in a statistically significant increase,
albeit small, in the mutation rate in the direct
assay. It is possible that an interaction with other
components of the urine extract might have sup-
pressed the mutagenic response to DMP in the
Ames assay. For example, in the extract of8 ml of
urine there was a 33-fold greater level of MMP
relative to DMP. This preponderance ofmonoester
could have affected the testerorganism, interfering
with oreliminatingitsmutagenicresponse to DMP.
The invitro ability ofskin and liverto metabolize
DMPwasinvestigated because ofthe demonstrated
importance ofmetabolism in determining the muta-
genic effect of DMP and the recognized fact that
these two tissues represent potential mutagenic/
carcinogenic sites for this compound. When the
rates of metabolism of DMP were compared on a
wet weight basis, liver had a 60-fold greater rate
than whole skin. This marked metabolic difference
highlights liver's enhanced capacity to metabolize
DMP to a nonmutagenic phthalate form and thus to
be protected from a potential mutagenic effect.
Conversely, skin, perhaps the only organ exposedMUTAGENICITY ASSESSMENT OF PHTHALATE ESTERS 109
to the entire body dose of DMP, may have little
inherent metabolic protection against the muta-
genic effects of DMP.
In considering the above along with the known
ability of many mutagens to bind macromolecules,
an investigation ofin vitro macromolecular binding
of14C-labeled DMP was compared in liverand skin.
The results from the binding experiments indicate
that DMP binds to epidermal macromolecules at a
severalfold greater rate than to liver macromole-
cules. Thus, DMP's lower rate of de-esterification
in the skin relative to liver was related inversely to
the higher rate of DMP's binding in the epidermis.
In spite ofthe substantial hepatic metabolism of
DMP by rats, the only positive mammalian muta-
genic response to this compound was observed by
Yurchenko (4) in rat liver. In light of the inverse
correlation ofbinding as well as ofmutagenicity to
metabolism of DMP, one would have expected the
liver to be relatively refractory to a mutagenic
event. Thus, based on Yurchenko's observation,
either the hepatic metabolism ofrats is insufficient
to protect the liver from chronic administration of
DMP or neither the Ames assay nor the TLC
analytical methodology used in these studies is
adequate to detect a mutagenic metabolite formed
from the products ofthe mono-esterase activity. If
the former explanation prevails, then skin with its
considerably lower level of mono-esterase activity
might well be at even greater risk than liver to
incur a mutagenic/carcinogenic event. On the other
hand, if the latter possibility is correct, then the
greaterrate ofhepatic monoesterase activitywould
suggest liver, rather than skin, as the primary
target site.
In conclusion, based on the results presented, we
would recommend an in vitro bioassay for the
carcinogenesis of DMP, particularly in view of the
wide spread exposure of the human population to
this compound. These results would argue for a
bioassay protocol that would include the topical
application of DMP.
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